Clinical Trial Update: PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating PD-L1 inhibition combined with focal radiotherapy in recurrent ovarian, primary peritoneal, and fallopian tube cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Status: UNKNOWN